Consent given pursuant to Sections 14 and 14A to the supply of the therapeutic goods specified by Aspen Pharmacare

Overview

The Therapeutic Goods Act 1989, enacted to regulate the provision of therapeutic goods in Australia, aims to protect public health and safety by ensuring these goods meet quality, safety, and efficacy standards. The Act empowers the Therapeutic Goods Administration (TGA) to control the import, supply, and advertising of therapeutic goods. One of the significant gaps it addresses is the need for comprehensive regulatory oversight to safeguard consumers from potentially harmful products. The consent granted under sections 14 and 14A of the Act, as illustrated in the case of the CARTIA LOW DOSE ASPIRIN 100mg tablet blister pack, demonstrates the TGA's role in balancing regulatory compliance with the timely availability of necessary therapeutic goods. This particular consent allowed Aspen Pharmacare Pty Ltd to supply a product with label discrepancies, addressing an immediate market need while awaiting compliance with forthcoming legislative changes. The Therapeutic Goods Act 1989, administered by the Commonwealth of Australia and enacted by the Australian Parliament, establishes a framework to ensure therapeutic goods are of acceptable quality, efficacy, and safety. The policy objective of this Act is to protect public health by regulating the therapeutic goods market, including the approval and monitoring of product labels. This legislative instrument facilitates the TGA's authority to issue consents that allow for temporary deviations from strict regulatory requirements, as seen in the case of the CARTIA LOW DOSE ASPIRIN 100mg tablet blister pack, ensuring that essential medications remain accessible to consumers while forthcoming regulatory changes are implemented.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacture, supply, and advertising of therapeutic goods within Australia. These entities can include individuals, corporations, and other legal persons or bodies that engage in activities related to therapeutic goods, which encompass a wide range of products such as medicines, medical devices, and blood products. The Act's jurisdiction extends across the Commonwealth of Australia, and it covers a broad spectrum of therapeutic goods and their associated activities. The Act provides for various regulatory controls, including licensing, advertising approvals, and post-market surveillance, to ensure that therapeutic goods are safe, of high quality, and effective. The Act also includes provisions for exemptions and thresholds, which may allow certain low-risk activities or products to be subject to less stringent regulatory requirements. Subordinate instruments, such as regulations and orders, can further extend or restrict the application of the Act by specifying additional details or conditions relevant to particular types of therapeutic goods or activities.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) provide the framework for consent to the supply of therapeutic goods that do not fully comply with certain regulatory requirements. In this case, Aspen Pharmacare Pty Ltd applied for and was granted consent to supply CARTIA LOW DOSE ASPIRIN 100mg tablet blister packs, with product labels that do not yet include all of the new warning statements mandated by a legislative instrument made by the Minister under subsection 3(5A) of the Act, effective from 12 December 2015. The consent allows for this non-compliance until the end of the year 2016, as specified in the consent terms. This consent ensures that the product can be supplied during a transitional period, allowing manufacturers time to update their labelling in accordance with new regulatory standards. The Act imposes several obligations on the parties involved in the supply of therapeutic goods. Firstly, it requires that the therapeutic goods supplied meet the standards set out in the Therapeutic Goods Order No. 69, which includes labelling requirements. Secondly, entities like Aspen Pharmacare must ensure that any transitional consent granted by the Secretary of the Department of Health adheres to the specified conditions, which in this case includes using previously approved TGA labels. These obligations ensure that the supply of therapeutic goods maintains a minimum level of safety and information transparency, even during transitional periods where full compliance with new regulations is not yet possible. Breaches of the Therapeutic Goods Act 1989 can result in significant legal consequences. While the specific provisions regarding penalties for non-compliance are not detailed in the extract, generally, the Act allows for substantial fines and potential imprisonment for individuals and corporations found guilty of breaches. For corporations, the maximum penalties can include fines up to hundreds of thousands of dollars, depending on the severity and intent of the breach. Civil consequences may also include court-ordered cessation of supply or recall of non-compliant goods. These stringent measures underscore the importance of adhering to the legislative requirements to ensure public health and safety.